Agenus rises on FDA's 'fast-track' tag for cancer therapy

Agenus

17/04/2023 14:19

** Shares of cancer therapy developer Agenus Inc  AGEN.O 
rise 5.41% to $1.52 premarket
    ** Company says U.S. FDA has granted "fast-track"
designation for its experimental combination therapy to treat a
type of colorectal cancer
    ** AGEN is testing drug candidate botensilimab in
combination with balstilimab in a mid-stage study in
non-microsatellite instability-high colorectal cancer patients
    ** FDA's fast-track tag is aimed to accelerate development
and review of products, which are intended to treat serious
diseases
    ** Up to Friday's close, stock down ~40% so far this year

 (Reporting by Mariam Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))